Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Objectives To evaluate the accuracy of routine data for costing inpatient resource use in a large clinical trial and to investigate costing methodologies. Design Final-year inpatient cost profiles were derived using (1) data extracted from medical records mapped to the National Health Service (NHS) reference costs via service codes and (2) Hospital Episode Statistics (HES) data using NHS reference costs. Trust finance departments were consulted to obtain costs for comparison purposes. Setting 7 UK secondary care centres. Population A subsample of 292 men identified as having died at least a year after being diagnosed with prostate cancer in Cluster randomised triAl of PSA testing for Prostate cancer (CAP), a long-running trial to evaluate the effectiveness and cost-effectiveness of prostate-specific antigen (PSA) testing. Results Both inpatient cost profiles showed a rise in costs in the months leading up to death, and were broadly similar. The difference in mean inpatient costs was £899, with HES data yielding ∼8% lower costs than medical record data (differences compatible with chance, p=0.3). Events were missing from both data sets. 11 men (3.8%) had events identified in HES that were all missing from medical record review, while 7 men (2.4%) had events identified in medical record review that were all missing from HES. The response from finance departments to requests for cost data was poor: only 3 of 7 departments returned adequate data sets within 6 months. Conclusions Using HES routine data coupled with NHS reference costs resulted in mean annual inpatient costs that were very similar to those derived via medical record review; therefore, routinely available data can be used as the primary method of costing resource use in large clinical trials. Neither HES nor medical record review represent gold standards of data collection. Requesting cost data from finance departments is impractical for large clinical trials. Trial registration number ISRCTN92187251; Pre-results.

[1]  Lord Bourne,et al.  Department for Communities and Local Government: Troubled families programme: transforming the lives of thousands of families , 2016 .

[2]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[3]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[4]  H. Mason,et al.  Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data , 2015, British Journal of Cancer.

[5]  J. Sterne,et al.  Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) , 2014, British Journal of Cancer.

[6]  W. Kraus,et al.  In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). , 2012, American Journal of Cardiology.

[7]  J. Lewsey,et al.  Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. , 2012, Health economics.

[8]  A. Adler,et al.  NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. , 2012, The Lancet. Oncology.

[9]  S. Wordsworth,et al.  What is the value of collecting detailed costing data in clinical trials? , 2011, Trials.

[10]  A. Grieve.  Adaptive designs: current status, future outlook , 2011, Trials.

[11]  Carl van Walraven,et al.  Administrative database research infrequently used validated diagnostic or procedural codes. , 2011, Journal of clinical epidemiology.

[12]  Denys T. Lau,et al.  End‐of‐Life and Formal and Informal Care Use of Community‐Dwelling Older Adults with Different Levels of Physical Disability , 2011, Journal of the American Geriatrics Society.

[13]  A. Braunack-Mayer,et al.  A randomised controlled trial to compare opt-in and opt-out parental consent for childhood vaccine safety surveillance using data linkage: study protocol , 2011, Trials.

[14]  Dyfrig A Hughes,et al.  Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  G. Naglie,et al.  Healthcare costs associated with prostate cancer: estimates from a population‐based study , 2010, BJU international.

[16]  H. Fukuda,et al.  Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. , 2009, Journal of evaluation in clinical practice.

[17]  Rodney P. Jones.  Limitations of the HRG tariff: the trim point , 2008 .

[18]  A. Noro,et al.  Health and social service use among old people in the last 2 years of life , 2007, European journal of ageing.

[19]  M. Bulsara,et al.  In‐patient hospital use in the last years of life: a Western Australian population‐based study , 2006, Australian and New Zealand journal of public health.

[20]  A. Gnanasakthy,et al.  COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL , 2003, International Journal of Technology Assessment in Health Care.

[21]  Taghreed Adam,et al.  COST-EFFECTIVENESS ANALYSIS: CAN WE REDUCE VARIABILITY IN COSTING METHODS? , 2003, International Journal of Technology Assessment in Health Care.

[22]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[23]  B. Mcgowan,et al.  Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation , 2002, Expert review of pharmacoeconomics & outcomes research.

[24]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[25]  Bruce Brady,et al.  Providing systematic guidance in pharmacoeconomic guidelines for analysing costs , 2012, PharmacoEconomics.

[26]  J. Malley,et al.  Younger Adults' Understanding of Questions for a Service User Experience Survey. Funded/commissioned by: The Health and Social Care Information Centre , 2006 .

[27]  Z. Mogyorósy,et al.  The main methodological issues in costing health care services: A literature review , 2005 .

[28]  Jan B Oostenbrink,et al.  Standardisation of costs: the Dutch Manual for Costing in economic evaluations. , 2002, PharmacoEconomics.